Your browser doesn't support javascript.
loading
Integrated computational and Drosophila cancer model platform captures previously unappreciated chemicals perturbing a kinase network.
Ung, Peter M U; Sonoshita, Masahiro; Scopton, Alex P; Dar, Arvin C; Cagan, Ross L; Schlessinger, Avner.
Afiliação
  • Ung PMU; Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
  • Sonoshita M; Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
  • Scopton AP; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
  • Dar AC; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
  • Cagan RL; Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
  • Schlessinger A; Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
PLoS Comput Biol ; 15(4): e1006878, 2019 04.
Article em En | MEDLINE | ID: mdl-31026276
ABSTRACT
Drosophila provides an inexpensive and quantitative platform for measuring whole animal drug response. A complementary approach is virtual screening, where chemical libraries can be efficiently screened against protein target(s). Here, we present a unique discovery platform integrating structure-based modeling with Drosophila biology and organic synthesis. We demonstrate this platform by developing chemicals targeting a Drosophila model of Medullary Thyroid Cancer (MTC) characterized by a transformation network activated by oncogenic dRetM955T. Structural models for kinases relevant to MTC were generated for virtual screening to identify unique preliminary hits that suppressed dRetM955T-induced transformation. We then combined features from our hits with those of known inhibitors to create a 'hybrid' molecule with improved suppression of dRetM955T transformation. Our platform provides a framework to efficiently explore novel kinase inhibitors outside of explored inhibitor chemical space that are effective in inhibiting cancer networks while minimizing whole body toxicity.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Quinases / Neoplasias da Glândula Tireoide / Carcinoma Neuroendócrino / Inibidores de Proteínas Quinases / Avaliação Pré-Clínica de Medicamentos / Antineoplásicos Idioma: En Revista: PLoS Comput Biol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Quinases / Neoplasias da Glândula Tireoide / Carcinoma Neuroendócrino / Inibidores de Proteínas Quinases / Avaliação Pré-Clínica de Medicamentos / Antineoplásicos Idioma: En Revista: PLoS Comput Biol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos